



Twist Bioscience to Present at Upcoming Virtual Investor Conferences

November 24, 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 24, 2020-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Jim Thorburn, CFO of Twist Bioscience, will present at the following upcoming virtual investor conferences:

- Piper Sandler 32nd Annual Virtual Healthcare Conference, recorded fireside chat available at 8:00 a.m. ET on Monday, November 30
- 2020 Evercore ISI HealthCONx Conference on Tuesday, December 1 at 1:50 p.m. ET

Both presentations can be accessed by visiting the "Investor Calendar" page of the investor relations section of the company's website [here](#). A replay of the presentations will be archived for a period of 90 days following the conclusion of the live event.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

View source version on [businesswire.com](https://www.businesswire.com/news/home/20201124005405/en/): <https://www.businesswire.com/news/home/20201124005405/en/>

Investor Contact:

Argot Partners
Maeve Conneighton
212-600-1902
maeve@argotpartners.com

Media Contact:

Angela Bitting
925-202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation